Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SPY002-072 · SPY002, SPY072

Other · developed by Spyre Therapeutics

Phase 2 Most advanced trial
SYRE Developer
1 Registered trials

What is SPY002-072?

SPY002-072 (also known as SPY002 and SPY072) is a drug studied in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SPY002, SPY072
Drug type
Other
Therapy area
Immunology
Developer
Spyre Therapeutics, Inc. (SYRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07148414 Phase 2 Rheumatoid Arthritis Active not recruiting SYRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Axial SpondyloarthritisAxSpAPsA (Psoriatic Arthritis)Psoriatic ArthritisRheumatic DiseasesRheumatic Joint DiseaseRheumatoid ArthritisRheumatologic Disease

More from Spyre Therapeutics

Follow SYRE, the company behind SPY002-072

See SYRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SYRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.